The global collaboration gives Lilly access to OmniAb’s specialist ion channel discovery and screening capabilities for an undisclosed therapeutic target and modality.

The reverse-merger transaction gives privately held Slate a Nasdaq listing and additional capital to advance its anti-PACAP migraine portfolio, led by clinical-stage monoclonal antibody SLTE-1009.

The portfolio collaboration combines Henlius’ biologics development and manufacturing capabilities with Sandoz’s ex-China commercial infrastructure, initially covering three biosimilars and an option on a recombinant human hyaluronidase programme.

The completed acquisition adds MediSix’s PEBL T-cell engineering technology, clinical pipeline and Singapore-based R&D team to IASO Bio’s existing cell therapy development, manufacturing and commercial capabilities.

The global collaboration gives Lilly access to OmniAb’s specialist ion channel discovery and screening capabilities for an undisclosed therapeutic target and modality.

The reverse-merger transaction gives privately held Slate a Nasdaq listing and additional capital to advance its anti-PACAP migraine portfolio, led by clinical-stage monoclonal antibody SLTE-1009.

The collaboration combines Henlius’ biologics development, manufacturing and supply capabilities with Sandoz’s ex-China commercial infrastructure, initially covering three biosimilars and an option on a recombinant human hyaluronidase programme.

The acquisition adds MediSix’s proprietary T-cell engineering technologies and pipeline to IASO Bio’s integrated cell therapy capabilities while strengthening its presence in Singapore and international markets.

The transaction creates a Nasdaq-listed fibrosis-focused company led by Redx’s management, with financing expected to fund the Phase II development of lead Crohn’s disease candidate RXC008 and provide cash runway into 2029.

The multi-program deal pairs Aizen’s DaX AI platform with an undisclosed San Diego biotechnology company to design oral peptide therapeutics against nominated immunology and neurology targets.

The agreement gives Zydus subsidiary Sentynl Therapeutics an option for exclusive US commercial and global manufacturing rights to Mereo BioPharma’s oral neutrophil elastase inhibitor, with Mereo leading preparations for pivotal development.

The acquisition would add a BLA-stage, one-time AAV gene therapy to PTC’s rare disease portfolio, with a rolling US submission expected to complete in the fourth quarter of 2026.

The amended agreement strengthens Exor's long-term commitment to Philips while allowing the healthcare technology investor to increase its maximum shareholding from 20% to 22%.

The collaboration combines HanchorBio's immuno-oncology platform with Taiwan's national precision oncology programme to support biomarker-driven clinical development and translational research.

The agreement gives Sentynl an exclusive pathway to commercialise the Phase III-ready rare lung disease therapy in the US while providing global manufacturing rights and funding support for late-stage development.

The acquisition would add Nordic Pharma’s €190 million-revenue business and Nordimet rheumatoid arthritis franchise while expanding Alfasigma’s direct commercial presence to 18 European countries and adding platforms in Canada and Japan.

The acquisition would add Caelo’s €40 million-revenue API and excipients business and establish the German company as the anchor of Medios’ planned European network for pharmaceutical compounding ingredients.

The acquisition adds SimoTech’s automation engineering and digital manufacturing expertise to Project Farma’s existing life sciences manufacturing services, creating a broader offering spanning facility strategy through GMP operations.

The collaboration pairs BeOne’s oncology pipeline with four clinical-stage RAS(ON) inhibitors while giving BeOne regional rights to the Revolution Medicines assets across selected Asian markets.

The collaboration will connect ChemoMetec’s XcytoMatic 30 cell counter with Roche’s Cedex Bio Analyzer and establish a joint go-to-market strategy for the combined bioprocess monitoring solution.